Dendritic Cell Therapy for Mesothelioma

In order to address the urgent unmet medical need in malignant mesothelioma, a consortium of leading European university hospitals is preparing a clinical study called DENIM (H2020MM04). The objective of the DENIM study is to demonstrate the efficacy and safety of dendritic cell-based immunotherapy in a randomized phase II/III clinical study.

DENIM clinical study

DENIM is an abbreviation of DENdritic cell Immunotherapy for Mesothelioma.

Read more about the DENIM study

H2020MM04: A European Effort

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 668769
About the consortium